JP7222901B2 - 抗ｐａｒ２抗体及びその使用 - Google Patents

抗ｐａｒ２抗体及びその使用 Download PDF

Info

Publication number
JP7222901B2
JP7222901B2 JP2019549512A JP2019549512A JP7222901B2 JP 7222901 B2 JP7222901 B2 JP 7222901B2 JP 2019549512 A JP2019549512 A JP 2019549512A JP 2019549512 A JP2019549512 A JP 2019549512A JP 7222901 B2 JP7222901 B2 JP 7222901B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
amino acid
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509762A (ja
JP2020509762A5 (enExample
Inventor
クレア・ドブソン
リチャード・ウィリアムズ
イアン・グレル
サダナ・ポディチェッティ
デイビッド・フェアマン
ピーター・ソーントン
フィリップ・ニュートン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2020509762A publication Critical patent/JP2020509762A/ja
Publication of JP2020509762A5 publication Critical patent/JP2020509762A5/ja
Priority to JP2023015469A priority Critical patent/JP2023055895A/ja
Application granted granted Critical
Publication of JP7222901B2 publication Critical patent/JP7222901B2/ja
Priority to JP2025043151A priority patent/JP2025102812A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019549512A 2017-03-16 2018-03-16 抗ｐａｒ２抗体及びその使用 Active JP7222901B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023015469A JP2023055895A (ja) 2017-03-16 2023-02-03 抗ｐａｒ２抗体及びその使用
JP2025043151A JP2025102812A (ja) 2017-03-16 2025-03-18 抗ｐａｒ２抗体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762472462P 2017-03-16 2017-03-16
US62/472,462 2017-03-16
US201862637766P 2018-03-02 2018-03-02
US62/637,766 2018-03-02
PCT/EP2018/056776 WO2018167322A1 (en) 2017-03-16 2018-03-16 Anti-par2 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023015469A Division JP2023055895A (ja) 2017-03-16 2023-02-03 抗ｐａｒ２抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2020509762A JP2020509762A (ja) 2020-04-02
JP2020509762A5 JP2020509762A5 (enExample) 2021-04-15
JP7222901B2 true JP7222901B2 (ja) 2023-02-15

Family

ID=61827709

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019549512A Active JP7222901B2 (ja) 2017-03-16 2018-03-16 抗ｐａｒ２抗体及びその使用
JP2023015469A Pending JP2023055895A (ja) 2017-03-16 2023-02-03 抗ｐａｒ２抗体及びその使用
JP2025043151A Pending JP2025102812A (ja) 2017-03-16 2025-03-18 抗ｐａｒ２抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023015469A Pending JP2023055895A (ja) 2017-03-16 2023-02-03 抗ｐａｒ２抗体及びその使用
JP2025043151A Pending JP2025102812A (ja) 2017-03-16 2025-03-18 抗ｐａｒ２抗体及びその使用

Country Status (22)

Country Link
US (3) US10836822B2 (enExample)
EP (1) EP3596125B1 (enExample)
JP (3) JP7222901B2 (enExample)
KR (1) KR102711884B1 (enExample)
CN (1) CN110446720B (enExample)
AU (3) AU2018235031B2 (enExample)
BR (1) BR112019018752A2 (enExample)
CA (1) CA3055251A1 (enExample)
CL (1) CL2019002626A1 (enExample)
CO (1) CO2019010975A2 (enExample)
CR (1) CR20190417A (enExample)
IL (1) IL269134B2 (enExample)
MA (1) MA49886A (enExample)
MX (1) MX2019010802A (enExample)
NZ (1) NZ757915A (enExample)
PH (1) PH12019502087A1 (enExample)
PT (1) PT3596125T (enExample)
SG (1) SG11201908056QA (enExample)
TW (1) TWI788332B (enExample)
UA (1) UA125757C2 (enExample)
WO (1) WO2018167322A1 (enExample)
ZA (1) ZA201906004B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023055895A (ja) * 2017-03-16 2023-04-18 メドイミューン・リミテッド 抗ｐａｒ２抗体及びその使用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
BR112013013354A2 (pt) 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
US12214216B1 (en) 2019-10-16 2025-02-04 Helen Feng Photon enhanced bone growth system and method
EP4454659A3 (en) 2020-08-18 2025-01-22 Cephalon LLC Anti-par-2 antibodies and methods of use thereof
GB202204159D0 (en) 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
AU2024212070A1 (en) 2023-01-25 2025-07-31 Medimmune Limited Migraine therapy
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009117481A1 (en) 2008-03-19 2009-09-24 Regeneron Pharmaceuticals, Inc. Use of protease-activated receptor 2 antagonists
JP2010532165A (ja) 2007-06-29 2010-10-07 アムジェン インコーポレイテッド Ｐａｒ−２に結合する抗原結合性タンパク質
JP2011530515A (ja) 2008-08-05 2011-12-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐａｒ−２活性化のエフェクターおよび炎症の調節におけるその使用
JP2013504577A (ja) 2009-09-09 2013-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
WO2004080373A2 (en) * 2003-03-11 2004-09-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
AU2005304963C1 (en) * 2004-11-04 2011-01-06 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JP6309521B2 (ja) * 2012-08-13 2018-04-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体
CN106459192B (zh) * 2014-06-30 2021-08-03 默克专利股份公司 具有pH依赖性抗原结合的抗TNFa抗体
TWI788332B (zh) * 2017-03-16 2023-01-01 英商梅迪繆思有限公司 抗-par2抗體及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010532165A (ja) 2007-06-29 2010-10-07 アムジェン インコーポレイテッド Ｐａｒ−２に結合する抗原結合性タンパク質
WO2009117481A1 (en) 2008-03-19 2009-09-24 Regeneron Pharmaceuticals, Inc. Use of protease-activated receptor 2 antagonists
JP2011530515A (ja) 2008-08-05 2011-12-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐａｒ−２活性化のエフェクターおよび炎症の調節におけるその使用
JP2013504577A (ja) 2009-09-09 2013-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Arteriosclerosis, Thrombosis, and Vascular Biology，1998年，Volume 18, Issue 5，pp. 825-832

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023055895A (ja) * 2017-03-16 2023-04-18 メドイミューン・リミテッド 抗ｐａｒ２抗体及びその使用

Also Published As

Publication number Publication date
US10836822B2 (en) 2020-11-17
KR102711884B1 (ko) 2024-10-02
IL269134B1 (en) 2024-03-01
PT3596125T (pt) 2025-11-27
AU2025203947A1 (en) 2025-06-19
CA3055251A1 (en) 2018-09-20
CR20190417A (es) 2019-12-06
US20230242639A1 (en) 2023-08-03
JP2023055895A (ja) 2023-04-18
SG11201908056QA (en) 2019-09-27
CN110446720A (zh) 2019-11-12
MX2019010802A (es) 2019-10-30
AU2021257983B2 (en) 2025-02-27
AU2018235031A1 (en) 2019-10-31
CN110446720B (zh) 2023-09-12
IL269134A (en) 2019-11-28
PH12019502087A1 (en) 2020-03-09
UA125757C2 (uk) 2022-06-01
TW201843176A (zh) 2018-12-16
JP2025102812A (ja) 2025-07-08
NZ757915A (en) 2023-05-26
WO2018167322A1 (en) 2018-09-20
CL2019002626A1 (es) 2019-12-06
AU2021257983A1 (en) 2021-11-25
MA49886A (fr) 2020-06-24
BR112019018752A2 (pt) 2020-05-05
IL269134B2 (en) 2024-07-01
US20210061905A1 (en) 2021-03-04
EP3596125B1 (en) 2025-11-19
JP2020509762A (ja) 2020-04-02
AU2018235031B2 (en) 2021-08-12
US20180305450A1 (en) 2018-10-25
EP3596125A1 (en) 2020-01-22
TWI788332B (zh) 2023-01-01
US11591389B2 (en) 2023-02-28
KR20190129925A (ko) 2019-11-20
CO2019010975A2 (es) 2019-10-21
ZA201906004B (en) 2025-10-29

Similar Documents

Publication Publication Date Title
JP7222901B2 (ja) 抗ｐａｒ２抗体及びその使用
JP6055055B2 (ja) ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体
EP3122776B1 (en) Fgf21 receptor agonists and uses thereof
TW202317643A (zh) 用於抗pacap抗體的組合物和方法
EA044850B1 (ru) Антитела к par2 и пути их применения
TW202519559A (zh) 雙特異性PD-L1xCD28抗體及其使用方法
TW202519547A (zh) 雙特異性PD-L1x4-1BB抗體及其使用方法
EA050327B1 (ru) Композиции и способы получения антител против pacap
HK1233666B (en) Fgf21 receptor agonists and uses thereof
HK1166509B (en) High affinity human antibodies to human protease-activated receptor-2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230203

R150 Certificate of patent or registration of utility model

Ref document number: 7222901

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150